- Home
- ABLV vs HOWL Comparison
ABLV vs HOWL Comparison
Compare ABLV & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- HOWL
- Stock Information
- Founded
- ABLV 2015
- HOWL 2017
- Country
- ABLV China
- HOWL United States
- Employees
- ABLV N/A
- HOWL N/A
- Industry
- ABLV
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- ABLV
- HOWL Health Care
- Exchange
- ABLV Nasdaq
- HOWL Nasdaq
- Market Cap
- ABLV 47.3M
- HOWL 50.3M
- IPO Year
- ABLV N/A
- HOWL 2021
- Fundamental
- Price
- ABLV $1.22
- HOWL $1.20
- Analyst Decision
- ABLV
- HOWL Strong Buy
- Analyst Count
- ABLV 0
- HOWL 3
- Target Price
- ABLV N/A
- HOWL $8.33
- AVG Volume (30 Days)
- ABLV 12.2K
- HOWL 643.1K
- Earning Date
- ABLV 04-23-2025
- HOWL 05-08-2025
- Dividend Yield
- ABLV N/A
- HOWL N/A
- EPS Growth
- ABLV N/A
- HOWL N/A
- EPS
- ABLV N/A
- HOWL N/A
- Revenue
- ABLV $128,932,647.00
- HOWL $1,143,000.00
- Revenue This Year
- ABLV N/A
- HOWL N/A
- Revenue Next Year
- ABLV N/A
- HOWL $900.00
- P/E Ratio
- ABLV N/A
- HOWL N/A
- Revenue Growth
- ABLV N/A
- HOWL N/A
- 52 Week Low
- ABLV $0.55
- HOWL $0.60
- 52 Week High
- ABLV $1.90
- HOWL $5.73
- Technical
- Relative Strength Index (RSI)
- ABLV 57.66
- HOWL 61.01
- Support Level
- ABLV $1.08
- HOWL $1.18
- Resistance Level
- ABLV $1.16
- HOWL $1.31
- Average True Range (ATR)
- ABLV 0.10
- HOWL 0.11
- MACD
- ABLV -0.00
- HOWL 0.02
- Stochastic Oscillator
- ABLV 88.10
- HOWL 68.83
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.